Insulin resistance and impaired beta cell function in rheumatoid arthritis.
OBJECTIVE
To identify factors that regulate glucose metabolism in rheumatoid arthritis (RA).


METHODS
We evaluated the homeostatic model assessment of insulin resistance (HOMA-IR) and beta cell function (HOMA-B) in 94 RA patients. We investigated the relationship between characteristics known to affect glucose metabolism in the general population (age, abdominal obesity [waist circumference], hypertension, antihypertensive therapy) as well as characteristics of RA (disease activity, glucocorticoid therapy) and insulin resistance and beta cell function.


RESULTS
Patients with high-grade inflammation (high-sensitivity C-reactive protein value >1.92 mg/liter) (n = 81) were more insulin resistant than patients with low-grade inflammation (n = 13), whereas beta cell function was similar in both groups. Insulin resistance and beta cell function were similar in both groups after adjustment for waist circumference. All recorded characteristics except for age were associated with HOMA-IR or/and HOMA-B in univariate analyses. In mixed regression models, abdominal obesity and patient's assessment of disease activity (by visual analog scale) were predictors of insulin resistance. The Disease Activity Score assessed using 28-joint counts for swelling and tenderness, tender joint count, and patient's assessment of disease activity were associated with reduced beta cell function, and the cumulative dose of glucocorticoids was associated with enhanced beta cell function. The cumulative glucocorticoid dose in all study patients was a mean of only 536 mg (95% confidence interval 239-1,173). In patients with high-grade inflammation, age was further associated with impaired beta cell function, whereas use of angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers was associated with enhanced beta cell function.


CONCLUSIONS
The modifiable factors of abdominal obesity, antihypertensive therapy, disease activity, and use of glucocorticoids appear to affect glucose metabolism in RA.
Dessein
Patrick H
PH
Johannesburg Hospital and Milpark Hospital, University of the Witwatersrand, Johannesburg, South Africa. Dessein@telkomsa.net
Joffe
Barry I
BI
D001172:Arthritis, Rheumatoid / Q000503:physiopathology*; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure; D015992:Body Mass Index; D049628:Body Size; D002097:C-Reactive Protein / Q000032:analysis; D003920:Diabetes Mellitus / Q000453:epidemiology; D005260:Female; D006706:Homeostasis; D006801:Humans; D007249:Inflammation / Q000097:blood / Q000503:physiopathology; D007333:Insulin Resistance / Q000502:physiology*; D007515:Islets of Langerhans / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D009765:Obesity / Q000503:physiopathology
D001786:Blood Glucose; D002097:C-Reactive Protein